MRDVision™: The future of MRD detection is here
Powering therapeutic breakthroughs with next-level ctDNA sensitivity.
Ultra-sensitive
As low as 1 ppm of limit of detection (LOD95)* delivering 100-1,000x greater sensitivity than existing MRD approaches
*At simulated >10,000 mutations, 100x read-depth
Panel free
Go beyond personalized panels with our whole genome baseline x whole genome monitoring, capturing rare variants in a complex tumor environment
Clinically validated
Rely on enhanced accuracy and reliability from a clinically validated assay performed by a CAP/CLIA laboratory, ready to use for both clinical and research settings
More data, more insights
Get highly curated whole genome cancer profiling data along with MRD assay report – deeper insights for deeper exploration
Submit a request
An exclusively whole genome approach delivering comprehensive insights, a simplified workflow, and ultra-precise monitoring.